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Abstract 
Background: Currently, in vivo model for personalised cancer drug testing is challenging. A zebrafish larvae xeno‑
graft model has been applied in recent years to cancer research, particularly for drug testing purposes, showing 
promising results in drug testing against patient‑derived tumour xenografts. Currently, these xenograft models apply 
imaging techniques to measure drug efficacy. However, this method carries several limitations, including timely 
imaging, thereby reducing the available number of tested fish and drugs. Here, we propose a PCR‑based fast assay to 
evaluate drug efficacy in a zebrafish larvae xenograft model.
Methods: We tested two primary and corresponding metastatic head and neck squamous cell carcinoma (HNSCC) 
cell lines and patient‑derived tongue cancer sample applying zebrafish larvae xenograft model. Cisplatin efficacy was 
tested using imaging technique and compared the results with PCR‑based methods. Drug screening of eight com‑
pounds was applied on both cell lines and patient sample using PCR.
Results: In a head‑to‑head comparison, all the three techniques (imaging, quantitative PCR, and droplet digital PCR) 
showed similar reduction of the cancer cells growth after cisplatin treatment. Using the quantitative PCR assay, we 
demonstrated a dose‑dependent response of HNSCC cells to cisplatin. Drug screening results of four HNSCC cell lines 
and patient sample revealed different drug efficacy between tested cancer cells.
Conclusion: We introduce a novel, easy, fast and cost‑effective PCR‑based in vivo zebrafish larvae assay to test the 
response of cell lines and clinical tumour samples to anti‑cancer drugs. This method goes hand‑by‑hand with the 
commonly used imaging assay.
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Background
Head and neck squamous cell carcinoma (HNSCC) is 
globally the eighth most common malignancy [1], char-
acterised by early metastasis and poor survival. Cur-
rently, primary treatment of HNSCC patients consists 
of surgery and (chemo)radiotherapy either alone or in 
combination [2]. Other approaches, such as targeted- 
and immunotherapy, also represent approved modalities, 
although they are not consistently applied as a first-line 
approach to treat HNSCC patients. However, these treat-
ments still offer limited efficacy given that 5-year survival 
amongst HNSCC patients is around 50% [3]. Once the 
tumour becomes resistant to radio- and chemotherapy, 
patients may receive various adjuvant treatments, such as 
cetuximab and pembrolizumab, to improve their survival 
[4–6]. This strategy leads to several problems includ-
ing unnecessary side effects, high costs and ineffective 
treatments. Therefore, personalised treatment of cancer 
patients in general and HNSCC patients in particular 
remains a necessity. Unfortunately, until now no practical 
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A zebrafish larvae xenograft has been used in recent 
years as a promising in  vivo model in cancer research 
[7–12]. This model carries several advantages, includ-
ing a large number of offspring, a small size (can fit in a 
96-well plate), a short experimental duration, a low cost 
and the possibility of completing high-throughput test-
ing. All of these factors encourage researchers to shift 
towards using zebrafish larvae in their experiments. 
Until recently, the zebrafish larvae model has primar-
ily been used to study cancer cell proliferation, metas-
tasis, tumour angiogenesis and drug testing [9, 13, 14]. 
Interestingly, two studies reported its application as a 
model for personalised colon and gastric cancer drug 
testing using patient-derived xenografts [7, 9]. Despite 
these positive findings, some drawbacks continue to sur-
round this model, including the evaluation technique of 
the drug response. Currently, imaging is the only avail-
able method for evaluating the tumour size and metasta-
sis. This method is time-consuming and poses limits on 
the number of fish per test, rendering it difficult for use 
in high-throughput screening. Currently, all of the pub-
lished reports about drug testing in zebrafish larvae are 
limited to three or four drugs. To address this problem, 
here, we introduce an easy, fast and low-cost PCR-based 
assay to evaluate the response of cancer cell lines and 
patient-derived xenografts to anti-cancer drugs. We also 




In this study, we used two primary and two meta-
static HNSCC cell lines (kindly provided by Dr. Reidar 
Grenman’s lab, University of Turku, Additional file  1: 
Table  S1). Cells were cultured in 75  cm2 flasks contain-
ing Dulbecco’s modified Eagle’s medium (DMEM)/F-12 
(Gibco, Paisley, UK) supplied with 10% heat-inactivated 
foetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/
ml streptomycin, 250  ng/ml fungizone and 50  μg/ml 
ascorbic acid. All cell lines were mycoplasma-free, tested 
using the PCR Mycoplasma Test Kit I/C (PromoKine, 
Heidelberg, Germany). To prepare the cell suspensions 
for injection, cells were detached from the flask using 
trypsin/EDTA and suspended in media at a concen-
tration of 5 × 105/µl. For imaging purposes, cells were 
stained using CellTrace Far Red (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions.
Patient sample
Our institutional Research Ethics Board (14.03.2016 
Eettmk 84) approved this study setting. Patient participa-
tion was voluntary and required informed consent. The 
patient had metastatic oral tongue cancer (Additional 
file 1: Table S1). After the surgical removal of the tumour 
and the metastatic lymph nodes, the patient received 
chemoradiotherapy (66/2  Gy for the primary tumour 
area + 50/2  Gy effective dose for the lymph nodes and 
cisplatin infusion 40  mg/m2 weekly for 6  weeks). After 
3  months, a CT scan showed no signs of recurrence or 
metastasis.
A fresh tissue sample was obtained perioperatively 
and placed in a 50-ml falcon tube containing ice-cold 
Hanks’ Balanced Salt solution (HBSS; supplied with 100 
U/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml 
fungizone). Tissue samples were stored on ice until fur-
ther processing. Each sample was placed in a petri dish 
and kept on ice containing HBSS. Necrotic tissues were 
removed using a scalpel. Vital tissue pieces were placed 
into a new petri dish containing HBSS and minced into 
small (1–2  mm) pieces with a scalpel. The tissue pieces 
were transferred to 15-ml falcon tube and centrifuged for 
5 min at 1000 rpm (200×g) at 4 °C. After centrifugation, 
the supernatant was discarded and a fresh HBSS buffer 
was added before another round of centrifugation. The 
supernatant was discarded, and the tissue piece pellet 
was suspended in a 5-ml HBSS buffer containing 1 mg/
ml collagenase type I from Clostridium histolyticum 
(Sigma-Aldrich, St. Louis, Mo, USA) and placed on a 
rocker platform at 37 °C. After 2 h of incubation, the tube 
was centrifuged and the supernatant was discarded and 
replaced with a fresh HBSS buffer before another round 
of centrifugation. The digested sample was suspended in 
an HBSS buffer, filtered using a 100-μm cell strainer (Fal-
con™ Cell Strainer, Fisher Scientific, NH, USA) and the 
flow-through (single cells) was collected and centrifuged. 
The supernatant was discarded and the cell pellet was 
suspended in DMEM/F-12 at a concentration of 5 × 105 
cells/µl.
Zebrafish larvae microinjection and drug administration
Experiments were done at the Zebrafish Unit at the 
University of Helsinki under the ethical permission 
(ESAVI/13139/04.10.05/2017) given by the regional 
state administrative agency. Wild-type zebrafish from 
the AB strain were maintained as described previously 
[15] in laboratory fish multi-rack system. The larvae 
were grown at 28.5  °C in an embryonic medium (5 mM 
NaCl, 0.17  mM KCl, 0.33  mM  CaCl2 and 0.33  mM 
 MgSO4; Sigma-Aldrich). Two-day-old fish were decho-
rionated, anesthetised with 0.04% Tricaine and 2 nl of a 
cell suspension (1000 cells) was microinjected into the 
perivitelline space. The larvae were transferred to a fresh 
embryonic medium in a 24-well plate and kept at 34  °C 
for 72 h and then collected for RNA isolation or fixed for 
imaging. The zebrafish larvae were treated with 1-phenyl 
2-thiourea (PTU) for imaging to avoid pigmentation. We 
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chose eight drugs (one chemotherapy agent and seven 
targeted-therapy agents) for this assay. Drug concentra-
tions were chosen based on our previous in  vitro drug 
testing as well as on the cytotoxicity test for the zebrafish 
larvae (Additional file  1: Table  S2). Drugs were diluted 
in the embryonic medium and DMSO was used as the 
negative control. Fish were kept in 24-well plates (5 fish 
per well in 1 ml of an embryonic medium). Twenty fish 
were used for each drug, where ten fish were pooled 
together to provide a sufficient signal during PCR ampli-
fication. The method is in compliance with the ARRIVE 
guidelines.
Imaging of the xenograft
Fish were imaged using a Zeiss Axio Imager (Carl Zeiss 
AG, Oberkochen, Germany) and a Leica TCS SP8 MP 
CARS (Leica Microsystems, Wetzlar, Germany; Addi-
tional file  2: Video S1), and the tumour area was meas-
ured using Matlab (MathWorks, Natick, MA, USA).
Quantitative and droplet digital PCR
RNA was extracted from the fish using the RNeasy Mini 
Kit (Qiagen, Düsseldorf, Germany) according to the 
manufacturer’s instructions. In total, 400 ng of RNA were 
used for the cDNA synthesis using an iScript cDNA syn-
thesis kit (Bio-Rad, Hercules, CA, USA). For quantitative 
PCR, 10-μl iQ SYBR green, 7-μl water and 1 μl of 250 nM 
of a primer solution were added to 2 μl of a cDNA sam-
ple. Zebrafish Glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) was used as the housekeeping gene.
For droplet digital PCR (ddPCR), 10  μl of QX200™ 
 EvaGreen® ddPCR™ Supermix (Bio-Rad Laboratories) 
and 1 μl of 900 nM of a primer were added to 2 μl of a 
cDNA sample. Samples, in addition to the Droplet-Gen-
eration Oil for EvaGreen (70 μl), were loaded into DG8 
cartridges and placed into a QX200™ Droplet-Generator 
(Bio-Rad Laboratories) for individual droplet generation. 
Droplets (40 μl) were then transferred to a 96-well PCR 
plate, sealed with the supplied foil in a PX1-PCR Plate 
Sealer instrument (Bio-Rad) and placed into the T100 
Thermal Cycler (annealing temperature = 60  °C). Next, 
the sealed plate was transferred to the QX200™ Droplet 
Digital™ PCR Systems (Bio-Rad Laboratories) to detect 
the completed PCR reactions in droplets. We used the 
QuantaSoft software, version 1.7.4.0917 (Bio-Rad Labo-
ratories), for data analysis. Additional file  1: Table  S3 
summarises the primer sequences.
Results
We first compared the already established imaging tech-
nique with quantitative PCR and ddPCR in a head-by-
head experiment. For quantitative PCR, we used human 
GAPDH to evaluate the number of human cells in the 
injected zebrafish larvae. We were unable to use specific 
epithelial cytokeratin markers in quantitative PCR since 
the signals fell below the detection levels. Therefore, we 
employed ddPCR, which successfully detected cytoker-
atin 17 mRNA. All three techniques showed a clear 
reduction in the tumour growth in response to cisplatin 
(Figs.  1, 2). The time required for conducting quantita-
tive PCR of 100 fish was 4.6 h which is around five times 
less than the imaging assay (21.3  h, Additional file  1: 
Table S4). Based on these results, we continued the drug 
testing with quantitative PCR given its convenience and 
wide availability in most research laboratories. 
Next, we evaluated the dose-dependent response to 
cisplatin. The curve showed a perfect negative correlation 
between the cisplatin dose and the human GAPDH signal 
(r = − 0.96, Fig. 3).
After these validation procedures for the technique, 
we initiated drug screening using eight drugs and four 
cancer cell lines. Cisplatin emerged as the most effective 
drug in almost all cell lines, while Afatinib showed no 
activity in any of the cell lines tested (Fig. 4, Additional 
file  1: Table  S5). Other drugs showed different levels of 
efficacy depending on the tested cell line (Fig.  4, Addi-
tional file 1: Table S5).
For the patient-derived (xenograft) tumour cells, cis-
platin yielded a modest effect (46% reduction) and the 
targeted-therapy (EGFR and mTOR inhibitors) revealed 
a strong effect (80–90% reduction, Fig.  4, Additional 
file  1: Table  S5). Interestingly, all the primary cancer 
cells (UT-SCC-24A, UT-SCC-42A, and tongue cancer 
Fig. 1 Reduction of the tumour area in zebrafish larvae after 
cisplatin treatment. Human tongue UT‑SCC‑24A carcinoma cells 
were labelled with CellTrace Far Red and injected in the perivitelline 
space of the zebrafish larvae. For the cisplatin‑treated group, 
cisplatin at a concentration of 3 µg/ml was added to the embryonic 
medium. Fish were kept at 34 °C for 3 days and then fixed with 4% 
formaldehyde, mounted on slides and imaged under a microscope. 
Scale bar = 100 µm
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patient sample) were less responsive to cisplatin com-
pared with the metastatic cancer cells (UT-SCC-24B and 
UT-SCC-42A).
Discussion
Here, we introduce an easy, fast and low-cost PCR-
based in  vivo assay to test anti-cancer drug responses 
in patient-derived tumour samples. The use of zebrafish 
larvae for drug testing in oncology and for personalised 
medicine specifically showed promising results, particu-
larly in terms of simulating real patient responses [7, 9]. 
In this work, we developed the assay further by suggest-
ing the PCR-based technique, which is easier and faster 
than the imaging assay. The PCR-based method allows 
for the use of a larger number of fish and tests a larger 
number of drugs.
We used both quantitative PCR, which is easy and 
available in almost all research and hospital laboratories, 
and ddPCR, which is more accurate and could detect 
mRNA at a very low expression level [16]. For the quanti-
tative PCR, we used human GAPDH, a highly expressed 
molecule typically used as the housekeeping gene to eval-
uate the number of human tumour cells. Unfortunately, 
in quantitative PCR, we could not detect any epithelial 
cancer cell markers such as cytokeratins, because of their 
low expression level. For this assay, we used the zebrafish 
GAPDH as the housekeeping gene, which remained sta-
ble  between the groups. Using a more sensitive ddPCR 
Fig. 2 Analysis of the tumour xenograft response in zebrafish larvae to cisplatin treatment using imaging, quantitative and droplet‑digital PCR. The 
evaluation of the cisplatin effect on a human tongue UT‑SCC‑24A tumour xenograft using imaging technique (a 6 fish for each group), quantitative 
PCR (b 20 fish for each group, with 10 fish pooled together) and ddPCR (c 20 fish for each group, with 10 fish pooled together). CK 17 = cytokeratin 
17
Fig. 3 Dose‑dependent response of the tumour xenograft to 
cisplatin treatment evaluated using quantitative PCR. Human larynx 
carcinoma UT‑SCC‑42A tumour xenograft in zebrafish larvae was 
subjected to different concentrations of cisplatin (0–3 µg/ml). The 
tumour response was evaluated using a quantitative PCR method. 
Each group had 20 fish, with 10 fish pooled together
Fig. 4 Anti‑cancer drug screening against four head and neck 
squamous cell carcinoma cell lines and one patient‑derived tongue 
carcinoma sample in zebrafish larvae. The heat map represents the 
response of the cancer cell lines and the patient‑derived tongue 
tumour to eight anti‑cancer drugs tested in zebrafish larvae using 
a quantitative PCR technique. Each group had 20 fish, with 10 fish 
pooled together. A reduction in the mRNA expression was plotted as 
a percentage relative to the control (100%)
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method, we detected cytokeratin 17. For patient-derived 
tumour samples specifically, we found that using ddPCR 
could be more precise in detecting the signal from epi-
thelial cancer cells alone. Due to the limited availabil-
ity of ddPCR and since it produced comparable results 
to quantitative PCR, we continued our assays using the 
quantitative PCR technique in order to provide an assay 
which could be easily adopted in most research and clini-
cal facilities.
The dose–response effect shown here and the differing 
responses to anti-cancer drugs enhance the reliability of 
the new assay. Additionally, testing patient-derived sam-
ples using this assay seems simple, fast and possible using 
basic laboratory equipment. More importantly, the entire 
testing procedure for patient samples can be completed 
within 1 week, which is critical to avoid treatment delays. 
This possibility may provide preliminary knowledge for 
the clinician regarding the most suitable and personal-
ised choice of available drugs for a specific patient in a 
time-efficient manner. In practice, this model appears 
superior to the mouse xenograft, which takes several 
weeks to establish drug testing. Additionally, in this 
system tumour cells are transferred from the patient to 
the zebrafish larvae within a few hours, without in vitro 
culturing, which may change their phenotype. Another 
advantage stems from the need of only 1000 cells per 
fish, which renders the method feasible even for a small 
tumour sample.
The primary limitation of the present zebrafish xeno-
graft assay is the different species between the host and 
the original species (human). This may affect the drug 
efficacy in some cancers, such as an endocrine-depend-
ent cancer, which should be kept in mind when evaluat-
ing the results [17].
Conclusion
We describe here an improvement to the existing 
zebrafish larvae xenograft assay applied to in  vivo per-
sonalised cancer-drug testing. Rather than measuring the 
tumour size using imaging techniques, we measured the 
drug efficacy using PCR.
Additional files
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